STARTRADER expands AI offering with 31 New US Share & ETF CFDs in Semiconductors, Optical Networking & NuclearJuly 31, 2026
Esports Foundation and adidas Announce Landmark Partnership to Outfit Every Team at the Inaugural Esports Nations CupJuly 30, 2026
Novo Nordisk’s amycretin achieves breakthrough obesity trial resultsJanuary 24, 2025 Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment.
